SCHEMBL8873365

SCHEMBL8873365

COc1ccccc1C1(O)CCC(OC)(OC)C2CN(Cc3ccccc3)CC21

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.46
CHRM4 P08173 2/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
DRD4 P21917 1/20 0.39
CCR8 P51685 1/20 0.39
ACHE P22303 2/20 0.38
POLB P06746 1/20 0.38
BACE1 P56817 1/20 0.38
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8875023 0.85 TACR1 (0.45) TACR1CHRM4MEN1KMT2ACHRM2
SCHEMBL8873598 0.81 MEN1 (0.46) TACR1CHRM4MEN1KMT2ACHRM2
SCHEMBL8875253 0.80 CHRM4 (0.44) TACR1CHRM4MEN1KMT2ACHRM2
SCHEMBL8875275 0.76 CHRM4 (0.40) TACR1CHRM4MEN1KMT2ACHRM2
SCHEMBL8875798 0.76 CHRM4 (0.41) CHRM4MEN1KMT2ADRD4ACHE
SCHEMBL8873403 0.76 MEN1 (0.46) CHRM4MEN1KMT2AACHEPOLB
SCHEMBL5805867 0.75 MEN1 (0.50) CHRM4MEN1KMT2ACHRM2CHRM5
SCHEMBL8684093 0.74 CHRM4 (0.41) TACR1CHRM4MEN1KMT2ACHRM2
SCHEMBL8545147 0.74 TACR1 (0.43) TACR1CHRM4MEN1KMT2ADRD4
SCHEMBL8874205 0.73 CHRM4 (0.42) CHRM4MEN1KMT2ADRD4ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5624950-A USEFUL IN TREATMENT OF ANALGESIA, INFLAMMATION, ASTHMA, ALLERGIES, CENTRAL NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS, IMMUNE SYSTEM DISORDERS, ANTISPASMODIC AGENTS, ANTIEMETIC AGENTS RHONE-POULENC RORER S.A. (FR) 1997-04-29 US disclosed